Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20694936 | 0.86 | GPR84 (0.36) | GPR84ATMTLR8KDM4EALDH1A1 | |
| SCHEMBL2200831 | 0.86 | TLR8 (0.47) | ATMTLR8MAPTMEN1KMT2A | |
| SCHEMBL6698577 | 0.84 | TLR8 (0.49) | TLR8MAPTMEN1KMT2A | |
| SCHEMBL158196 | 0.83 | TLR8 (0.48) | TLR8KDM4EALDH1A1MAPTGAA | |
| SCHEMBL20694916 | 0.83 | TLR8 (0.48) | TLR8KDM4EALDH1A1MAPTGAA | |
| SCHEMBL9065394 | 0.83 | TLR8 (0.48) | TLR8KDM4EALDH1A1MAPTGAA | |
| SCHEMBL560035 | 0.83 | TLR8 (0.48) | TLR8KDM4EALDH1A1MAPTGAA | |
| SCHEMBL3403921 | 0.83 | TLR8 (0.48) | TLR8KDM4EALDH1A1MAPTGAA | |
| SCHEMBL5500478 | 0.82 | TLR8 (0.47) | TLR8KDM4EALDH1A1MAPTGAA | |
| SCHEMBL63968 | 0.77 | KDM4E (0.41) | GPR84ATMTLR8KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220069354-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2022-03-03 | — | — | US | disclosed |
| CN-113631536-A | Fluorene derivative and use thereof | 日产化学株式会社 | 2021-11-09 | — | — | CN | disclosed |
| EP-3904337-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | FUJIFILM Wako Pure Chemical Corporation (JP) | 2021-11-03 | — | — | EP | disclosed |
| EP-3439097-B1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM WAKO PURE CHEMICAL CORP (JP) | 2020-12-30 | — | — | EP | disclosed |
| WO-2020203594-A1 | FLUORENE DERIVATIVE AND USE THEREOF | 日産化学株式会社 | 2020-10-08 | — | — | WO | disclosed |
| US-10727534-B2 | Electrolyte solution containing magnesium ions | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2020-07-28 | — | — | US | disclosed |
| WO-2020138377-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | 富士フイルム和光純薬株式会社 | 2020-07-02 | — | — | WO | disclosed |
| US-20190131657-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3439097-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | FUJIFILM Wako Pure Chemical Corporation (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | SEQUELLA, INC. | 2009-11-12 | — | — | US | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1052481-A | Lipoid category-A with immunocompetence and anti-tumor activity is like thing | SANKYO CO (JP) | 1991-06-26 | — | — | CN | disclosed |
| US-4644074-A | AGAINST DEGRADATION BY KAOLIN CLAY BY ADDING AN AMINE | SWS SILICONES CORPORATION (US) | 1987-02-17 | — | — | US | disclosed |
| EP-0197540-A2 | Use of amines for stabilizing polysiloxane fluids | WACKER-CHEMIE GMBH (DE) | 1986-10-15 | — | — | EP | disclosed |
| US-4612055-A | Stabilized blends of thiofunctional polysiloxane fluids and organopolysiloxane fluids and a process for stabilizing the same | SWS SILICONES CORPORATION (US) | 1986-09-16 | — | — | US | disclosed |
| US-4263151-A | TREATING WITH BASE AND SULFONATE DISPERSANT | PETROLITE CORPORATION (US) | 1981-04-21 | — | — | US | disclosed |
| US-4104036-A | TO IMPROVE OCTANE RATING | ATLANTIC RICHFIELD COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4104293-A | Oil-soluble chromium compositions | PETROLITE CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
| US-4076638-A | ALUMINA-SULFONIC OR CARBOXYLIC ACID REACTION PRODUCT; FUEL ADDITIVES, CORROSION INHIBITORS | PETROLITE CORPORATION (US) | 1978-02-28 | — | — | US | disclosed |
| US-4056479-A | FUEL ADDITIVE | PETROLITE CORPORATION (US) | 1977-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10727534-B2 | Electrolyte solution containing magnesium ions | MLX, PRDX1, PRDX6 | GPR84 1179/4885ATM 3775/4885TLR8 2468/4885 |
| US-20220069354-A1 | SULFUR-BASED ELECTROLYTE SOLUTION FOR MAGNESIUM CELL | SLC26A3, PRDX4, PRDX2 | GPR84 688/4885ATM 4487/4885TLR8 4273/4885 |
| US-20090281054-A1 | COMPOSITIONS AND METHODS COMPRISING CAPURAMYCIN ANALOGUES | TTPA, PHOSPHO1, CAPG | GPR84 3827/4885ATM 4558/4885TLR8 1392/4885 |
| US-20190131657-A1 | ELECTROLYTE SOLUTION CONTAINING MAGNESIUM IONS | MLX, PRDX1, PRDX6 | GPR84 1179/4885ATM 3775/4885TLR8 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.